Association of darolutamide and EBRT

Phase 2

BAYER (BAYRY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

BAYRYPhase 2$42.5B

Association of darolutamide and EBRT Phase 2 Est. Readout

Association of darolutamide and EBRT• Prostate Cancer62

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

7 competitors in Prostate Cancer

CADLaglatimagene besadenovec

Phase 3

CASIPanzem® NCD

Phase 2

SNYCabazitaxel XRP6258

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT05346848

Last updated: 9/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts